Dual Immunotherapy Boosts Survival in Metastatic NSCLC

(MedPage Today) -- Adding two immunotherapeutic drugs to chemotherapy significantly improved progression-free survival (PFS) and overall survival (OS) in untreated metastatic non-small cell lung cancer, according to a secondary analysis of a randomized...